FDA commissioner Stephen Hahn speaks as President Trump listens at the White House on August 23, 2020. (Alex Brandon/AP Images)

Ex­clu­sive: We asked for bio­phar­ma's opin­ion about the plas­ma EUA. The in­dus­try of­fered a dou­ble-bar­reled re­sponse

FDA com­mis­sion­er Stephen Hahn took to Twit­ter Mon­day night to walk back some of his un­sub­stan­ti­at­ed com­ments about plas­ma’s im­pact on Covid-19 and push a claim that the con­tro­ver­sial EUA was all done by the book, but the dam­age he’s done to the agency’s rep­u­ta­tion for in­de­pen­dence and in­tegri­ty may not be so easy to re­pair.

And that’s with­in the bio­phar­ma in­dus­try, which has been high­ly fa­vor­able to re­cent reg­u­la­to­ry trends on drug re­views and ac­cess.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.